ITRM
Iterum Therapeutics plc
NASDAQ · Healthcare · Biotechnology · IE
$0.03
−10.98%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +16.7%
- EBIT
- +23.3%
- EPS
- +62.5%
- Free cash flow
- +43.6%
- Operating cash flow
- +43.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +37.2%
- EBIT
- +60.6%
- Net income
- +35.4%
- EPS
- +57.4%
- Free cash flow
- +32.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2025